Kronborg O, Jørgensen O D, Fenger C, Rasmussen M
Department of Surgery A, Odense University Hospital, Linde Alle 32, DK-5230 Odense, Denmark.
Scand J Gastroenterol. 2004 Sep;39(9):846-51. doi: 10.1080/00365520410003182.
Two large true population studies in Europe have shown a significant reduction in mortality from colorectal cancer (CRC) by screening with a faecal occult blood test. In one trial conducted in Funen County, 61,933 individuals (aged 45-75 years) were randomly allocated either to a control group or to receive a biennial Hemoccult-II test.
These individuals were followed from 1985 to 2002 and 9 screening rounds were performed.
First screening was accepted by 67% (20,672). Positivity rates varied between 0.8% and 3.8%, and the cumulative proportion of the test group having colonoscopy was 5.3%. Screen-detected CRC was early (Dukes' A) in 36% compared to 11% among controls. Incidence of CRC was unchanged, but mortality was reduced by 11%. This figure increased to 43% in persons participating in all 9 rounds. No more than 8,558 were screened at the 9th round. Patients with CRC detected between screenings had better survival than controls. Death rates from causes other than CRC among participants never became higher than among controls.
The lesser reduction in mortality from CRC of 11% compared to 18% after 5 screening rounds may be explained by the decrease in the number screened. Efficacy in those screened supports the introduction of countrywide screening in Denmark, but it must be ascertained that acceptability, proportion of early CRC and logistics all reach the same standard as in the randomized trial.
欧洲两项大型真实人群研究表明,通过粪便潜血试验进行筛查可显著降低结直肠癌(CRC)死亡率。在菲英岛进行的一项试验中,61933名年龄在45至75岁之间的个体被随机分为对照组或接受每两年一次的Hemoccult-II检测。
对这些个体从1985年至2002年进行随访,并进行了9轮筛查。
首次筛查的接受率为67%(20672人)。阳性率在0.8%至3.8%之间,试验组接受结肠镜检查的累积比例为5.3%。筛查发现的结直肠癌中,36%为早期(杜克A期),而对照组为11%。结直肠癌发病率未变,但死亡率降低了11%。在参加全部9轮筛查的人群中,这一数字增至43%。第9轮筛查人数不超过8558人。筛查间隔期发现的结直肠癌患者的生存率高于对照组。参与者中除结直肠癌外其他原因导致的死亡率从未高于对照组。
与5轮筛查后18%的死亡率降低幅度相比,结直肠癌死亡率降低幅度较小(11%),这可能是由于筛查人数减少所致。对接受筛查者的有效性支持在丹麦全国范围内开展筛查,但必须确保可接受性、早期结直肠癌比例和后勤保障均达到与随机试验相同的标准。